Paid Clinical Trials Des Moines
Discover 238 paid clinical trials in Des Moines, Iowa. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Venetoclax with cBTKiA Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.
Sponsor:
Genentech, Inc.
Location:
Code:
NCT06524375
Conditions
Chronic Lymphocytic Leukemia
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Venetoclax
cBTKi Monotherapy
autoRICRemote Ischemic Conditioning Using the autoRIC
Sponsor:
CellAegis US, Inc.
Location:
Code:
NCT03318575
Conditions
Ischemia-Reperfusion Injury
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
autoRIC
autoRIC Sham
VolrustomigA Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Sponsor:
AstraZeneca
Location:
Code:
NCT06129864
Conditions
Locally Advanced Head and Neck Squamous Cell Carcinoma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
volrustomig
Elacestrant vs. Standard Endocrine TherapyA Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor:
Stemline Therapeutics, Inc.
Location:
Code:
NCT06492616
Conditions
Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Elacestrant
Anastrozole
Letrozole
Exemestane
Tamoxifen
Venetoclax & ObinutuzumabA Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Sponsor:
AbbVie
Location:
Code:
NCT06428019
Conditions
Chronic Lymphocytic Leukemia
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Venetoclax
Acalabrutinib
Obinutuzumab
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Acalabrutinib & RituximabStudy of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Sponsor:
AstraZeneca
Location:
Code:
NCT05952024
Conditions
Diffuse Large B-Cell Lymphoma
Eligibility Criteria
Sex: All
Age: 65 - 70+
Healthy Volunteers: Not accepted
Interventions
Acalabrutinib
Rituximab
Navtemadlin & RuxolitinibStudy of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Sponsor:
Kartos Therapeutics, Inc.
Location:
Code:
NCT06479135
Conditions
Myelofibrosis
Post-PV MF
Post-ET Myelofibrosis
Primary Myelofibrosis
MF
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Navtemadlin
Navtemadlin placebo
Ruxolitinib
Dara-VCD vs. ChemotherapyComparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT06022939
Conditions
AL Amyloidosis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Autologous Hematopoietic Stem Cell Transplantation
Biopsy
Biospecimen Collection
Bone Marrow Aspiration
Bone Marrow Biopsy
Lenalidomide & NivolumabTesting the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04609046
Conditions
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bone Marrow Aspiration and Biopsy
Computed Tomography
Echocardiography Test
Lenalidomide
Lumbar Puncture
Tafasitamab & LenalidomiderealMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Sponsor:
Incyte Corporation
Location:
Code:
NCT04981795
Conditions
Diffuse Large B-cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Tafasitamab